A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer-Reference-Cited by-同舟云学术

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer

Published:2015-06-05 Issue:1 Volume:152 Page:95-117
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Generali Daniele,Venturini Sergio,Rognoni Carla,Ciani Oriana,Pusztai Lajos,Loi Sherene,Jerusalem Guy,Bottini Alberto,Tarricone Rosanna

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-015-3453-9/fulltext.html

Reference83 articles.

1. Roche H, Vahdat LT (2011) Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 22:1000–1010

2. Fernandez Y, Cueva J, Palomo AG et al (2010) Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev 36:33–42

3. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529

4. Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30:870–884

5. Burris HA III, Lebrun F, Rugo HS et al (2013) Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 119:1908–1915

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of everolimus‐based therapy in advanced triple‐positive breast cancer: Experience from three cancer centers in China;Thoracic Cancer;2023-11-07

2. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer;Cancer Treatment Reviews;2022-12

3. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy;Molecular Biomedicine;2022-03-04

4. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study;Cancer Investigation;2021-12-22

5. Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis;Cancers;2021-03-22